Genmab — Maj 2015
-
Earlier this month, Johnson & Johnson (NYSE:JNJ) announced plans to file applications by the end of this year for U.S. and European regulatory approval of daratumumab as a new treatment for relapsed multiple myeloma. The updated trial results released this morning will support those applications, which could result in daratumumab becoming available to treat myeloma patients outside of clinical trials by the first half of next year. http://www.myelomabeacon.com/news/2015/05/30/daratumumab-multip
-
Interview med Dr. Lonial Sagar - http://www.cancernetwork.com/asco-2015-hematology/results-multiple-myeloma-trials?cid=tw
-
Giver svar på dette spørgsmål - Cancer Network: You’re presenting the results of this phase II study of daratumumab monotherapy. Could you describe the agent and what we know so far about its potential in treating multiple myeloma and maybe other tumor types? - See more at: http://www.cancernetwork.com/asco-2015-hematology/results-multiple-myeloma-trials?cid=tw#sthash.YeWxTfpK.dpuf
-
Tror i snart jeg kan bestille ny
MC -
Ja..og jeg overvejer lige nu en Ww Polo fra 2001 i stedet for Carinaen.
-
God nok. Jan har sponsoreret mig et livsforbrug af Matador Mix
-
Jej drømmer vist....kursen skal i 1000 før det er virkelighed
-
Jeg har to Pandaer og en Carina Fantomas.
-
Kom nu ikke for godt igang...jeg har to biler, to motorcykler og to traktorer .....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind